Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Selexis and OSE expand business relationship
July 2017
SHARING OPTIONS:

GENEVA & NANTES, France—Selexis SA and OSE Immunotherapeutics SA have inked a commercial license agreement granting OSE access to high-performance research cell banks (RCBs) from the Selexis SUREtechnology Platform. This agreement is built on a previous deal announced by the companies in November 2016 and will support the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127, which is being developed as a potential treatment for inflammatory bowel diseases.
 
“The broad applicability of our technology, coupled with our robust cell lines, provides our partners with the opportunity to continue working with us long-term across their drug development cycles. We look forward to helping OSE Immunotherapeutics realize the full potential of OSE-127,” said Dr. Marco Bocci, Selexis’ vice president of licensing and business development. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.